MMP and OME: Study of the Expression of MMPs in OME in Children With Atrophy of the Eardrum

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT03611842
Collaborator
INM : institut des neurosciences Montpellier (Other)
35
1
2
17.5

Study Details

Study Description

Brief Summary

Metalloproteinases (MMPs) constitute a family of endopeptidases that cleaves the extracellular matrix as collagen included in the eardrum. Activity of MMP has been shown in some otitis media with effusion (OME) fluids. These enzymes could be directly linked to the prosnostic of OME as it may damage the eardrum and leads to tympanic atrophy.

The main goal of the study is to find out the correlation between activity of MMPs and tympanic atrophy. The investigator will also study if there is any clinical predictive factors in relation to the level of MMPs.

Condition or Disease Intervention/Treatment Phase
  • Other: preservation of mucosal otitis media

Detailed Description

The investigator will include 35 children under 12 years old with OME and who need tympanostomy or tube placement under general anesthesia. Middle ear effusion will be collected, divided in two and frozen.

The investigator will perform ELISA tests to measure the level of MMP2 MMP9 MMP7 et TIMP2 (inhibitor of MMPs). The investigator want to compare the level of MMPs between healthy eardrum and atrophic membrane.

Clinical data will be collected such as age, gender, chronicity of the OME, quality of the eardrum and middle ear effusion type to see if there is any difference when MMPs level is higher.

Study Design

Study Type:
Observational
Actual Enrollment :
35 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Study of the Expression of MMPs (Metalloproteinase Matricial) in OME (Otitis Media With Effusion) in Children Under Twelve Years Old With Atrophy of the Eardrum
Actual Study Start Date :
Sep 30, 2018
Actual Primary Completion Date :
Nov 1, 2018
Actual Study Completion Date :
Nov 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Healthy eardrum

OME (otitis media with effusion)with normal tympanic membrane

Other: preservation of mucosal otitis media
Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum

Atrophic eardrum

OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket

Other: preservation of mucosal otitis media
Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum

Outcome Measures

Primary Outcome Measures

  1. Microscopic evaluation of the quality of the eardrum : normal or atrophic [before surgery]

    Microscopic evaluation of the quality of the eardrum : normal or atrophic

Secondary Outcome Measures

  1. biochemical assay of the level of TIMP [1 day]

    biochemical assay of the level of TIMP

  2. biochemical assay of the level of MMPs [1 day]

    biochemical assay of the level of MMPs

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • every children under 12 yo operated on in Gui de Chauliac Hospital
Exclusion criteria:
  • when effusion is not possible to collect (too thick or amount of fluid not enough)

Collection of both MEE on each ear when OME is bilateral. We will perform the tests on only one ear. The other one will be kept in case of technical issue. A random draw will establish which ear will be tested.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Uhmontpellier Montpellier France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier
  • INM : institut des neurosciences Montpellier

Investigators

  • Principal Investigator: Lylou Casteil Baume, ENT resident, University Hospital, Montpellier

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT03611842
Other Study ID Numbers:
  • RECHMPL18_0306
First Posted:
Aug 2, 2018
Last Update Posted:
Apr 19, 2019
Last Verified:
Jul 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2019